Cadila Healthcare Limited — Budesonide Exporter Profile
Indian Pharmaceutical Exporter · #8 for Budesonide · $787.7K export value · DGFT Verified
Cadila Healthcare Limited is the #8 Indian exporter of Budesonide with $787.7K in export value and 22 verified shipments. Cadila Healthcare Limited holds a 0.4% market share in Budesonide exports across 5 countries. The company exports 41 pharmaceutical products worth $34.9M across 17 therapeutic categories.
Cadila Healthcare Limited — Budesonide Export Profile: Buyers & Destinations
Where Does Cadila Healthcare Limited Export Budesonide?
| Country | Value | Shipments | Share |
|---|---|---|---|
| UNITED STATES | $250.0K | 5 | 40.6% |
| SRI LANKA | $211.3K | 24 | 34.3% |
| VIETNAM | $119.2K | 4 | 19.4% |
| KENYA | $18.9K | 2 | 3.1% |
| SUDAN | $9.6K | 1 | 1.6% |
| MAURITIUS | $6.8K | 3 | 1.1% |
Cadila Healthcare Limited exports Budesonide to 6 countries. The largest destination is UNITED STATES accounting for 40.6% of Cadila Healthcare Limited's Budesonide shipments, followed by SRI LANKA (34.3%) and VIETNAM (19.4%). These destinations reflect Cadila Healthcare Limited's established distribution network and regulatory approvals in key markets.
Who Are the Top Buyers of Budesonide from Cadila Healthcare Limited?
| Buyer | Country | Value | Orders |
|---|---|---|---|
| SUNSHINE HEALTHCARE LANKA LIMITED | SRI LANKA | $194.8K | 21 |
| NORTHSTAR HEALTHCARE UNLIMITED COMP | UNITED STATES | $150.0K | 3 |
| ZYDUS PHARMACEUTICALS USA INC | UNITED STATES | $100.0K | 2 |
| HAPHARCO J S C BRANCH | VIETNAM | $69.2K | 3 |
| HAPHARCOJ S CBRANCH | VIETNAM | $50.0K | 1 |
| GALAXY PHARMACEUTICAL LIMITED | KENYA | $18.9K | 2 |
| SUNSHINE HEALTHCARE LANKA LTD | SRI LANKA | $16.5K | 3 |
| M PHARMA CO LTD | SUDAN | $9.6K | 1 |
| FTM MAURITIUS LTD | MAURITIUS | $5.8K | 2 |
| FTM MAURITIUS LIMITED | MAURITIUS | $976 | 1 |
Cadila Healthcare Limited supplies Budesonide to 10 buyers globally. The largest buyer is SUNSHINE HEALTHCARE LANKA LIMITED (SRI LANKA), followed by NORTHSTAR HEALTHCARE UNLIMITED COMP (UNITED STATES) and ZYDUS PHARMACEUTICALS USA INC (UNITED STATES). These buyers represent pharmaceutical distributors, hospital groups, and government procurement agencies in their respective markets.
What Is India's Total Budesonide Export Value and How Much Does Cadila Healthcare Limited Contribute?
India exported $70.6M worth of Budesonide through 9,145 shipments from 275 suppliers to 115 countries, serving 609 buyers globally. Cadila Healthcare Limited contributes $787.7K to this total, accounting for 0.4% of India's Budesonide exports. Cadila Healthcare Limited ships Budesonide to 6 countries through 10 buyers.
What Is the Average Shipment Value for Cadila Healthcare Limited's Budesonide Exports?
Cadila Healthcare Limited's average Budesonide shipment value is $35.8K per consignment, based on 22 shipments totaling $787.7K. The largest destination is UNITED STATES (40.6% of Cadila Healthcare Limited's Budesonide exports).
How Does Cadila Healthcare Limited Compare to Other Indian Budesonide Exporters?
Cadila Healthcare Limited ranks #8 among 275 Indian Budesonide exporters with a 0.4% market share. The top 3 exporters are CIPLA LIMITED ($53.0M), SUN PHARMACEUTICAL INDUSTRIES LIMITED ($7.8M), ZYDUS LIFESCIENCES LIMITED ($2.4M). Cadila Healthcare Limited processed 22 shipments to 5 destination countries.
What Budesonide Formulations Does Cadila Healthcare Limited Export?
| Product Description / Formulation | Value | Shipments |
|---|---|---|
| BUDESONIDE ENTERIC COATED CAPSULE 3 MG - | $250.0K | 5 |
| FORMONIDE 400 MDI 1'S- HFAFORMOTEROL FUMARATE & BUDESONIDE INHALATION1 X 1 UNIT | $80.5K | 7 |
| FORMONIDE 400 RESPICAPS BUDESONIDE AND | $75.4K | 5 |
| FORMONIDE 200 INHALER BUDESONIDE & FORM | $75.1K | 4 |
| FORMONIDE 200 INHALERBUDESONIDE & FORMOTEROL FUMARATE INHALER1X120MDI | $50.0K | 1 |
| FORMONIDE 200 RESPICAPSBUDESONIDE AND FORMOTEROL FUMARATE RESPICAP3X10 | $22.2K | 6 |
| FORMONIDE 400 RESPICAPSBUDESONIDE AND F | $16.5K | 3 |
| FORMONIDE 200 MDI 1'S- HFAFORMOTEROL FUMARATE & BUDESONIDE INHALATION1 X 1 UNIT | $13.5K | 2 |
| FORMONIDE 400 INHALER BUDESONIDE & FORMOTEROL FUMARATE INHALER 1X120MDI | $13.1K | 1 |
| FORMONIDE200HFA INHCFC FREE120MDIBUDESONIDE & FORMOTEROL FUMARATE INHALER1X 120 MD | $9.6K | 1 |
Cadila Healthcare Limited exports 14 distinct Budesonide formulations including tablets, capsules, syrups, and combination drugs. The top formulation is BUDESONIDE ENTERIC COATED CAPSULE 3 MG - with 5 shipments worth $250.0K. Notable combination products include fixed-dose combinations with other active ingredients, meeting diverse global regulatory requirements.
Regulatory Requirements: Exporting Budesonide to Key Markets
What Cadila Healthcare Limited must comply with to export Budesonide to its top destination countries
United States — FDA
Approval Process
ANDA (Abbreviated New Drug Application) for generics. Indian manufacturing site must pass FDA pre-approval inspection. Drug Master File (DMF) required for APIs.
Timeline: 10–18 months for ANDA approval
GMP & Export Requirements
FDA cGMP compliance (21 CFR 210/211); facility inspection by FDA
Drug Listing with FDA; Export Certificate from CDSCO India; Import Alert screening via FDA PREDICT system
Note: Subject to FDA Import Alerts. Open Form 483 observations can block all exports from a facility.
Regulatory information is provided for general reference based on publicly available guidelines. Requirements vary by formulation, dosage form, and therapeutic classification. Exporters should consult qualified regulatory affairs professionals for case-specific guidance.
How Does Cadila Healthcare Limited Compare to Nearest Budesonide Exporters?
Exporters ranked immediately above and below #8 by export value
| # | Supplier | Export Value | Shipments | Countries | Avg/Shipment |
|---|---|---|---|---|---|
| 5 | AHLCON PARENTERALS INDIA LIMITED | $1.1M | 22 | 2 | $49.2K |
| 6 | AXA PARENTERALS LIMITED | $1.0M | 43 | 9 | $23.6K |
| 8 | CADILA HEALTHCARE LIMITED ★ | $787.7K | 22 | 5 | $35.8K |
| 7 | MEDISPRAY LABORATORIES PRIVATE LIMITED | $600.0K | 12 | 1 | $50.0K |
| 9 | ALTHEA PHARMA PRIVATE LIMITED | $578.6K | 119 | 1 | $4.9K |
Cadila Healthcare Limited ranks #8 among 275 Indian Budesonide exporters. Average shipment value of $35.8K compared to the market average of $256.7K. The closest competitors by value are AHLCON PARENTERALS INDIA LIMITED and AXA PARENTERALS LIMITED.
Which Indian Ports Ship Budesonide Exports?
| Port | Shipments | % Share |
|---|---|---|
| SAHAR AIR | 1,990 | 21.8% |
| DELHI AIR CARGO ACC (INDEL4) | 1,616 | 17.7% |
| DELHI AIR | 1,404 | 15.4% |
| SAHAR AIR CARGO ACC (INBOM4) | 1,213 | 13.3% |
| Delhi Air | 419 | 4.6% |
| Bombay Air | 386 | 4.2% |
| NHAVA SHEVA SEA (INNSA1) | 303 | 3.3% |
| Delhi Air Cargo | 152 | 1.7% |
What Other Respiratory Products Does Cadila Healthcare Limited Export?
Cadila Healthcare Limited also exports these respiratory products. Each links to the detailed product page.
Geopolitical & Trade Policy Impact on Cadila Healthcare Limited's Budesonide Exports
The current geopolitical landscape presents both challenges and opportunities for Indian pharmaceutical exporters like Zydus. The escalating conflict in the Middle East has disrupted key maritime routes, particularly the Red Sea and Suez Canal, leading to longer transit times and increased freight costs. Major carriers have suspended or restricted transits, extending transit times by 10–20 days and raising freight rates by 40–50% on key India–Europe routes. (livemint.com) This situation poses significant challenges for time-sensitive pharmaceutical shipments, especially temperature-sensitive medicines. (economictimes.indiatimes.com)
Conversely, U.S.–China trade tensions have prompted the U.S. to impose tariffs on Chinese pharmaceutical imports, creating an opportunity for Indian exporters to fill the supply gap. However, the U.S. has also introduced tariffs on Indian imports, including a 25% "reciprocal" tariff, followed by an additional 25% penalty tied to India's continued imports of Russian oil, bringing the total duty to 50%. (en.wikipedia.org) While pharmaceuticals are currently exempt, the potential for future tariffs necessitates strategic planning.
In the European Union, compliance with the Falsified Medicines Directive (FMD) is crucial. The FMD mandates stringent serialization and traceability requirements to prevent counterfeit medicines from entering the supply chain. Non-compliance can result in restricted market access, making adherence to these regulations imperative for exporters like Zydus.
Cadila Healthcare Limited — Regulatory Compliance & Quality Standards
Maintaining compliance with international regulatory standards is paramount for Indian pharmaceutical exporters. The U.S. FDA, WHO, and EU Good Manufacturing Practice (GMP) guidelines set stringent quality benchmarks. Any lapses can lead to import alerts, product recalls, or facility shutdowns. For instance, in 2019, Zydus's Moraiya facility received an Official Action Indicated (OAI) classification from the U.S. FDA, indicating that regulatory and/or administrative actions were recommended. (moneycontrol.com) Such events underscore the importance of robust quality assurance systems.
The evolving regulatory landscape demands continuous investment in compliance infrastructure. The EU's Falsified Medicines Directive and the U.S. Drug Supply Chain Security Act (DSCSA) require advanced serialization and traceability measures. Non-compliance can result in restricted market access, making adherence to these regulations imperative for exporters like Zydus.
About Cadila Healthcare Limited
Cadila Healthcare Limited exports 41 products worth $34.9M. Beyond Budesonide, top products include Carvedilol, Losartan, Spironolactone, Iron, Chloroquine. View the complete Cadila Healthcare Limited profile for full portfolio analysis.
Market Intelligence
Latest developments and market context
Detailed market intelligence for Budesonide — including regulatory updates, trade policy changes, and competitive landscape analysis — will be available in an upcoming update. This section will feature AI-researched insights from verified industry sources, government notifications, and market reports.
Official References & Regulatory Resources
- CDSCO India
- Pharmexcil
- IBEF — India Pharma Industry
- Ministry of Commerce — Pharma Exports
- India Trade Statistics (DGFT)
Verify manufacturer licensing and export certifications with the official agencies above.
Research Methodology & Data Transparency
Suresh Sormare
Verified AuthorPharmaceutical Export-Import Analyst & Trade Intelligence Expert
Suresh Sormare is a pharmaceutical export-import analyst with deep expertise in Indian Customs (DGFT) data, HS code classification, and global pharmaceutical supply chains. His analysis covers 10M+ shipment records across 150+ countries and is used by manufacturers, procurement agencies, and trade consultants worldwide. Suresh specializes in identifying verified suppliers and buyers from customs records, mapping bilateral pharmaceutical trade corridors, analyzing tariff structures and regulatory frameworks across 170+ destination markets, and benchmarking competitive positioning for finished pharmaceutical formulations. His methodology combines granular customs transaction data with regulatory intelligence from FDA, EMA, WHO, CDSCO, and 40+ national drug authorities to deliver actionable trade insights for the pharmaceutical formulations sector.
linkedin.com/in/sureshsormarePrimary Data Source
All trade data is sourced from Indian Customs (DGFT) official shipping bill records — the authoritative government database for India's pharmaceutical trade. Each verified record contains exporter name, consignee (buyer) name, detailed product description, quantity, declared FOB value (USD), port of loading, destination country, and shipment date.
Analysis Methodology
- 1.Product Matching: Budesonide shipments identified using fuzzy matching on DGFT product description fields, validated against Indian Pharmacopoeia nomenclature.
- 2.Supplier Identification: Cadila Healthcare Limited matched across shipments using name normalization, accounting for company name formatting variations.
- 3.Statistical Normalization: Shipment values are statistically normalized to ensure accurate market share representation. This removes the impact of unusually large one-off transactions that could distort company rankings.
- 4.Verified Records: This page is backed by 39 individual customs records matching Cadila Healthcare Limited exporting Budesonide, covering 14 formulations to 6 countries via 10 buyers.
Government-Sourced Data
Official DGFT customs records
Transparent Methodology
Calculations fully disclosed above
Global Coverage
Exports to 115+ countries, 609+ buyers
Expert-Reviewed
Analyzed by pharmaceutical trade specialists
Get Budesonide Export Data from Cadila Healthcare Limited
Access shipment-level details, pricing data, buyer connections, and competitive analysis for Cadila Healthcare Limited's Budesonide exports. TransData Nexus provides verified Indian Customs (DGFT) data trusted by pharmaceutical trade professionals worldwide.
Cadila Healthcare Limited
Full Company Profile →
41 products · $34.9M total trade · 17 categories
Budesonide Stats
Company Overview
Top Products by Cadila Healthcare Limited
Related Analysis
Need Detailed Export Data?
Access shipment-level records, pricing trends, and buyer contacts for Cadila Healthcare Limited.
Request DemoView Pricing →Data Source
Trade data sourced from Indian Customs (DGFT) export shipment records. Values represent FOB export value in USD. Market share calculated relative to total Indian pharmaceutical exports for Budesonide. For current shipment-level data, contact TransData Nexus.